Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

Recent & Breaking News (TSX:RVX)

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"

Canada NewsWire August 4, 2015

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

Canada NewsWire July 21, 2015

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

Canada NewsWire July 21, 2015

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink

Canada NewsWire July 8, 2015

Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement

Canada NewsWire June 30, 2015

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Canada NewsWire June 22, 2015

Resverlogix to Present at the 2015 Bio International Convention

Canada NewsWire June 17, 2015

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA

Canada NewsWire June 8, 2015

Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Canada NewsWire June 1, 2015

Resverlogix (T.RVX) inks licensing and equity deal with China-based Shenzhen Hepalink

Stockhouse Editorial April 27, 2015

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

Canada NewsWire April 27, 2015

Resverlogix Receives Two Patents for RVX-208 in China

Canada NewsWire April 7, 2015

Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)

Canada NewsWire March 16, 2015